Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.
about
Isolation and chimerization of a highly neutralizing antibody conferring passive protection against lethal Bacillus anthracis infectionDevelopment & validation of a quantitative anti-protective antigen IgG enzyme linked immunosorbent assay for serodiagnosis of cutaneous anthraxAnthrax vaccination strategiesImmunization of mice with formalin-inactivated spores from avirulent Bacillus cereus strains provides significant protection from challenge with Bacillus anthracis AmesContribution of immunological memory to protective immunity conferred by a Bacillus anthracis protective antigen-based vaccineNovel and unique diagnostic biomarkers for Bacillus anthracis infection.Detection of specific Bacillus anthracis spore biomarkers by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.Genome-based bioinformatic selection of chromosomal Bacillus anthracis putative vaccine candidates coupled with proteomic identification of surface-associated antigens.Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccinesIdentification of a protein subset of the anthrax spore immunome in humans immunized with the anthrax vaccine adsorbed preparation.Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen.Proteomic profiling and identification of immunodominant spore antigens of Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis.Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine.Morphogenesis of the Bacillus anthracis sporeDevelopment and implementation of a single-chain Fv antibody for specific detection of Bacillus anthracis spores.Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin.Efficacy of a vaccine based on protective antigen and killed spores against experimental inhalational anthraxAnthrax prevention and treatment: utility of therapy combining antibiotic plus vaccine.Identification and characterization of novel and potent transcription promoters of Francisella tularensis.Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen.Search for correlates of protective immunity conferred by anthrax vaccine.Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization.Anthrax spores make an essential contribution to vaccine efficacyA recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection.Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs.Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challengeSearch for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening.The development of new vaccines against Bacillus anthracis.Identification of the immunogenic spore and vegetative proteins of Bacillus anthracis vaccine strain A16R.Differential proteomic analysis of the Bacillus anthracis secretome: distinct plasmid and chromosome CO2-dependent cross talk mechanisms modulate extracellular proteolytic activitiesSearch for Bacillus anthracis potential vaccine candidates by a functional genomic-serologic screen.Development of an improved vaccine for anthraxBacterial infectious disease control by vaccine development.Serological Correlate of Protection in Guinea Pigs for a Recombinant Protective Antigen Anthrax Vaccine Produced from Bacillus brevis.Fully virulent Bacillus anthracis does not require the immunodominant protein BclA for pathogenesis.Identification of in vivo-expressed immunogenic proteins by serological proteome analysis of the Bacillus anthracis secretome.Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.Bacillus subtilis as a tool for vaccine development: from antigen factories to delivery vectors.Development of an improved selective agar medium for isolation of Yersinia pestis.Differential contribution of Bacillus anthracis toxins to pathogenicity in two animal models
P2860
Q28389813-65013DE8-CBDC-42E9-9A22-FB243CFB02CCQ28391701-F18F8BCB-6BD4-4CC1-B2A7-3BC804A3B5D3Q28392248-4B885C3F-E13D-490E-9D7C-1A4CE1D03042Q28392659-C57EE217-2F78-4308-84DE-A15701229CDBQ28393904-509BF112-84C7-4C3A-A205-60C80769828EQ30157179-883DA0EC-2A44-4348-99EB-28DEB9999008Q30780001-E147182B-7D01-419F-A194-5EE8B907108BQ30783500-070F9268-3BAB-4E18-9E9C-7928466352AFQ31126626-1B0772DB-40E4-44F5-A713-2D0AF89A863FQ33222054-0542D880-3548-435F-BBAC-A21217701464Q33224077-BACDC0C8-D60F-49A5-AA29-335C689B62D6Q33256633-DA1DB9F8-D3E7-407D-A094-3DB66AB3160CQ33258307-E4CB6728-ADA8-4699-B962-E4981B11A1B6Q33264045-539DA444-C81F-4B12-88A3-2AE3756C90C9Q33304155-A5C8D310-4177-4730-949B-FD16FD25ED67Q33306246-630D2FF4-9195-4B76-BEAA-3AF3F797362BQ33396429-4BD24866-43D2-4B8E-87E3-C47D6C1C43C4Q33505445-E8629A8F-0A6E-46F9-A037-C7FC8E79BB89Q33782558-DA4B54CE-582A-439B-99CE-30215ED80D2EQ33883273-CE047F97-F980-460E-835D-6A0B5BF55D03Q34007168-4B420BA0-D335-4C81-9607-048BE2E053FDQ34117219-28BEEFA9-9A05-4246-96CA-CF6532CEC365Q34117857-E2FC1492-39DA-4EA0-AF83-192A71605147Q34119476-DB41495F-D64D-4FD6-94A1-700C61C404A0Q34182441-8055342E-C94D-43B0-96FD-2A1BD7044EC5Q34194628-BD7E2F5D-EF1B-45E3-BDFB-D559D8B21F5CQ34262140-B1F8E9EA-EED6-4033-B8DC-FC1FB49DF6D0Q34384018-1FFEFFC9-8DED-4AF9-BE0E-1346387E62A3Q34629406-8C719F0D-0D51-4670-AB26-C3A76270726CQ34696713-E15A8D0F-A14E-4C49-8294-4B3C0DF574F6Q34721071-A424B384-E107-4F1A-965D-47BD0BC3FF3EQ34744925-1E24350D-D7A0-4C5B-92C5-9C032BACE2FCQ34785982-124AD9F8-5043-484E-A50C-9B16C5B231CEQ35026166-CB31511F-54FD-4B14-AFD2-DCB6D2A44685Q35688979-BBC51ED1-8AB5-4A80-A5B2-1FE413F2C8FCQ35913411-A64EA986-551C-4B8D-8777-2FB640773E30Q35914307-274D28F6-CBB3-4A4D-BDFE-A17F4ABF8932Q36030835-FF979219-4591-4CA1-B2AB-AB0C82BF02FAQ36049051-EB382D5F-BA92-4E55-930D-9D46C01A337CQ36211202-28223259-58E9-44DE-BC7A-5C5383BAF027
P2860
Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Attenuated nontoxinogenic and ...... cines protect against anthrax.
@ast
Attenuated nontoxinogenic and ...... cines protect against anthrax.
@en
type
label
Attenuated nontoxinogenic and ...... cines protect against anthrax.
@ast
Attenuated nontoxinogenic and ...... cines protect against anthrax.
@en
prefLabel
Attenuated nontoxinogenic and ...... cines protect against anthrax.
@ast
Attenuated nontoxinogenic and ...... cines protect against anthrax.
@en
P2093
P2860
P1476
Attenuated nontoxinogenic and ...... cines protect against anthrax.
@en
P2093
A Shafferman
E Elhanany
H Rosenberg
I Mendelson
P2860
P304
P356
10.1128/IAI.68.8.4549-4558.2000
P407
P577
2000-08-01T00:00:00Z